Q1 25 EPS
$2.46
BEAT +2.62%
Est. $2.40
Q1 25 Revenue
$13.34B
BEAT +3.27%
Est. $12.92B
vs S&P Since Q1 25
-16.2%
TRAILING MARKET
ABBV +14.7% vs S&P +30.9%
Market Reaction
Did ABBV Beat Earnings? Q1 2025 Results
AbbVie opened 2025 on solid footing, posting first-quarter revenue of $13.34 billion, up 8.4% year over year and ahead of the $12.92 billion consensus estimate by 3.27%, while adjusted diluted EPS of $2.46 beat the $2.40 Wall Street forecast by 2.62%… Read more AbbVie opened 2025 on solid footing, posting first-quarter revenue of $13.34 billion, up 8.4% year over year and ahead of the $12.92 billion consensus estimate by 3.27%, while adjusted diluted EPS of $2.46 beat the $2.40 Wall Street forecast by 2.62%. The immunology franchise was the clear engine of growth, generating $6.26 billion in revenue as Skyrizi surged 70.5% to $3.42 billion and Rinvoq climbed 57.2% to $1.72 billion, more than compensating for Humira's continued biosimilar-driven erosion. Neuroscience also contributed meaningfully, rising 16.1% to $2.28 billion, though aesthetics remained a soft spot, declining 11.7% to $1.10 billion on weaker consumer demand for Botox Cosmetic and Juvederm. AbbVie used the strong quarter to lift its full-year 2025 adjusted diluted EPS guidance to a range of $12.09 to $12.29, though management noted the outlook excludes any impact from potential pharmaceutical tariffs, a topic on which the company has publicly advocated for tax reform over trade measures as the more effective lever for expanding U.S. Manufacturing.
Key Takeaways
- • Skyrizi revenue growth of 70.5% driven by strong demand across indications
- • Rinvoq revenue growth of 57.2% with expanding indications including GCA approval in EU
- • Neuroscience portfolio growth of 16.1% led by Botox Therapeutic and migraine franchise
- • U.S. net revenues grew 10.4% year-over-year
- • Creon revenue grew 24.6% year-over-year
ABBV YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
ABBV Revenue by Segment
With YoY comparisons, source: SEC Filings
ABBV Revenue by Geography
With YoY comparisons, source: SEC Filings
“AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year.”
— Robert A. Michael, Q1 2025 Earnings Press Release
ABBV Earnings Trends
ABBV vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABBV EPS Trend
Earnings per share: estimate vs actual
ABBV Revenue Trend
Quarterly revenue: estimate vs actual
ABBV Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.65 | — | $15.00B | +1.93% |
| Q4 25 MISS FY | $3.35 | $2.71 | -19.10% | $16.62B | +1.22% |
| FY Full Year | $9.94 | $10.00 | +0.64% | $61.16B | +0.33% |
| Q3 25 BEAT | $1.78 | $1.86 | +4.23% | $15.78B | +1.23% |
| Q2 25 BEAT | $2.91 | $2.97 | +2.14% | $15.42B | +2.61% |
| Q1 25 BEAT | $2.40 | $2.46 | +2.62% | $13.34B | +3.27% |